Eickhoff A, Martin W, Hartmann D, Eickhoff J C, Möhler M, Galle P R, Riemann J F, Jakobs R
Medical Department C, Klinikum Ludwigshafen gGmbH, Bremserstr.79, Ludwigshafen D-67063, Germany.
Br J Cancer. 2006 Jun 5;94(11):1572-4. doi: 10.1038/sj.bjc.6603174.
Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.
先前已有关于吉西他滨（GEM）和表柔比星（EPI）在胰腺癌中潜在协同相互作用的描述。本试验中的最大耐受剂量为吉西他滨1000 mg/m²和表柔比星45 mg/m²。中位疾病进展时间为5.1个月，中位生存时间为7.4个月。这种联合方案似乎耐受性良好，并显示出有前景的临床活性。
